Lucid Diagnostics Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own80.40% Shs Outstand37.39M Perf Week0.00%
Market Cap60.30M Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float5.67M Perf Month1.45%
Income-56.20M PEG- EPS next Q-0.34 Inst Own5.90% Short Float / Ratio2.35% / 1.32 Perf Quarter0.72%
Sales0.40M P/S150.74 EPS this Y-93.10% Inst Trans-5.68% Short Interest0.13M Perf Half Y-12.50%
Book/sh0.62 P/B2.26 EPS next Y24.00% ROA-126.00% Target Price5.22 Perf Year-57.45%
Cash/sh0.52 P/C2.68 EPS next 5Y- ROE-168.50% 52W Range1.11 - 3.64 Perf YTD2.94%
Dividend- P/FCF- EPS past 5Y- ROI-200.60% 52W High-61.54% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low26.70% ATR0.13
Employees74 Current Ratio2.90 Sales Q/Q-66.70% Oper. Margin- RSI (14)44.31 Volatility8.64% 9.80%
OptionableNo Debt/Eq0.22 EPS Q/Q-1.30% Profit Margin- Rel Volume6.86 Prev Close1.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume101.31K Price1.40
Recom1.60 SMA20-9.24% SMA500.47% SMA200-26.47% Volume695,430 Change0.72%
Dec-27-21Initiated Ascendiant Capital Markets Buy $16
Nov-08-21Initiated Needham Buy $17
Nov-08-21Initiated Cantor Fitzgerald Overweight $21
Nov-08-21Initiated BTIG Research Buy $14
Mar-31-23 12:45PM
Mar-20-23 09:03PM
Mar-17-23 04:15AM
Mar-16-23 01:22AM
Mar-15-23 02:43AM
07:09PM Loading…
Mar-14-23 07:09PM
Mar-03-23 08:15AM
Feb-28-23 08:30AM
Feb-15-23 08:30AM
Jan-18-23 06:24AM
Jan-17-23 04:05PM
Jan-11-23 08:00AM
Dec-22-22 08:25AM
08:25AM Loading…
Dec-15-22 08:25AM
Dec-12-22 08:43AM
Dec-08-22 08:25AM
Dec-01-22 08:25AM
Nov-15-22 04:20PM
Nov-14-22 04:40PM
Nov-10-22 08:25AM
Nov-09-22 08:25AM
Nov-02-22 08:25AM
Aug-15-22 04:25PM
Aug-11-22 08:25AM
Aug-04-22 08:25AM
Aug-02-22 08:25AM
Aug-01-22 08:25AM
08:25AM Loading…
Jul-18-22 08:25AM
Jul-04-22 01:57PM
May-13-22 08:25AM
May-11-22 04:00PM
May-09-22 08:25AM
Apr-25-22 08:25AM
Apr-14-22 12:02PM
Apr-04-22 08:25AM
Mar-30-22 08:25AM
Mar-29-22 04:11PM
Mar-28-22 04:47PM
Mar-24-22 08:25AM
Mar-23-22 08:25AM
Mar-08-22 08:30AM
Mar-07-22 08:30AM
Mar-04-22 08:25AM
Mar-03-22 08:25AM
Feb-24-22 08:25AM
Feb-15-22 08:25AM
Feb-10-22 08:25AM
Jan-19-22 07:26AM
Jan-12-22 08:25AM
Jan-06-22 08:30AM
Dec-01-21 08:30AM
Nov-17-21 08:30AM
Nov-16-21 04:13PM
Nov-11-21 08:30AM
Nov-03-21 08:30AM
Oct-28-21 08:30AM
Oct-21-21 12:59PM
Oct-18-21 06:09PM
Oct-14-21 12:12PM
Oct-13-21 10:15PM
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lapidus StanleyDirectorSep 20Sale1.7033,86457,683135,456Sep 22 11:46 AM